• First patient dosed in gene therapy trial for scleroderma

    10 days ago - By Healio

    The first adult patient has been dosed in a phase 1/2 clinical trial of FCX-103 for the treatment of scleroderma, Castle Creek Biosciences announced in a press release.
    FCX-103, an investigational gene therapy candidate, is an autologous fibroblast genetically modified using lentivirus and encoded for matrix metalloproteinase 1, a protein that breaks down collagen. It is being investigated for the treatment of moderate to severe localized scleroderma.
    The open-label, single-cohort trial will evaluate the safety of FCX-103, as well as assess fibrosis at targeted sclerotic lesions at various...
    Read more ...